サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1589012

薬物動態サービスの世界市場

Pharmacokinetics Services

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
薬物動態サービスの世界市場
出版日: 2024年11月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

薬物動態サービスの世界市場は2030年までに16億米ドルに達する見込み

2023年に10億米ドルと推定される薬物動態サービスの世界市場は、分析期間2023-2030年にCAGR 6.5%で成長し、2030年には16億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである低分子は、CAGR6.1%を記録し、分析期間終了までに12億米ドルに達すると予想されます。大型分子セグメントの成長率は、分析期間中CAGR 7.9%と推定されます。

米国市場は2億7,190万米ドルと推定、中国はCAGR6.1％で成長すると予測

米国の薬物動態サービス市場は、2023年に2億7,190万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR6.1％で、2030年までに2億4,920万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.8%と5.4%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の薬物動態サービス市場- 主要動向と促進要因のまとめ

なぜ薬物動態サービスが医薬品開発に不可欠なのか？

薬物動態サービスは医薬品開発プロセスの基本要素であり、医薬品が体内でどのように移動するか、つまり吸収、分布、代謝、排泄（ADME）を理解する上で重要な役割を果たします。これらのサービスは、薬物の挙動に関する洞察を提供し、研究者が治療効果のために最適な投与量、投与頻度、デリバリー方法を決定するのに役立ちます。薬物動態試験から得られるデータは、新薬が臨床試験、ひいては市場に出る前に、その安全性と有効性を確保するために極めて重要です。薬物動態サービスは、詳細な分析を通じて、薬剤が体内で活性を維持する時間、肝臓で分解される方法、排泄される効率を評価します。

競争の激しい製薬業界において、競合は開発サイクルの早い段階で潜在的な問題を特定することで、後発医薬品が失敗するリスクを低減します。これらのサービスは、毒性や効果のない治療を避けるために正確な投与が不可欠な、治療域の狭い医薬品にとって特に重要です。薬物動態サービスは、薬剤が体内を通過する詳細なマップを提供することで、臨床試験のデザインにおいて、より多くの情報に基づいた意思決定を可能にし、最終的には規制当局の承認取得の可能性を高めます。

技術の進歩は薬物動態サービス市場をどのように形成していますか？

最先端技術の統合は、薬物動態サービスを変革し、その精度、スピード、スケーラビリティを向上させました。最も重要な進歩の一つは、複数の薬剤候補を同時に迅速に評価できるハイスループットスクリーニング（HTS）技術の使用です。HTSは高度な計算モデルと組み合わされることで、開発の初期段階において薬剤の薬物動態プロファイルをより効率的に予測することを可能にし、大規模なin-vivo試験の必要性を減らし、候補化合物選定のスケジュールを早める。さらに、人工知能（AI）と機械学習（ML）の応用は、薬物動態学におけるデータ解析に革命をもたらしました。AIアルゴリズムは、薬物動態試験から得られた膨大なデータセットを解析し、様々な患者集団における薬剤の挙動を予測することができ、従来の統計的手法を超える洞察を提供します。これらの技術はまた、潜在的な薬物間相互作用や副作用を示す可能性のあるパターンの特定にも役立ちます。AIを活用した薬物動態モデリングは、医薬品開発に関連するコストと時間を大幅に削減し、より正確な投与レジメンと個別化医療アプローチを可能にする可能性を秘めています。さらに、質量分析や液体クロマトグラフィーなどの生物分析技術の進歩により、薬物動態研究の感度と精度が向上しています。これらの技術により、研究者は生体試料中の薬物濃度をより高い精度で検出・定量できるようになり、薬物がどのように代謝・排泄されるかをより詳細に理解できるようになった。薬物動態サービスにおけるこれらの技術の利用拡大により、規制当局への申請や臨床試験デザインに不可欠な、より堅牢で信頼性の高いデータ収集が業界を牽引しています。

薬物動態サービスのアウトソーシングは市場にどのような影響を与えているか？

製薬企業やバイオテクノロジー企業が医薬品開発パイプラインの合理化を図る中で、薬物動態サービスの専門CRO（医薬品開発業務受託機関）へのアウトソーシングは一般的な動向となっています。アウトソーシングにより、企業は多額の内部投資をすることなく、最新の技術、専門知識、インフラを利用することができます。この動向は、社内で薬物動態試験を実施するためのリソースが不足している可能性のある中小規模の製薬会社で特に顕著です。

CROと提携することで、これらの企業は、最先端の生物分析ツールを備え、薬物代謝・薬物動態（DMPK）の専門家が常駐する専門的な薬物動態サービスを活用することができます。また、アウトソーシングは、個々の医薬品開発プログラムのニーズに基づいてサービスを拡大または縮小する柔軟性を提供し、初期段階および後期段階の医薬品候補の両方にとって費用対効果の高いソリューションとなります。さらに、多くのCROが世界に展開しているため、製薬会社は複数の地域で薬物動態試験を実施することができ、これは異なる市場の規制要件に対応する上で極めて重要です。

アウトソーシングのもう一つの主要な推進力は、特に生物製剤、遺伝子治療、個別化医療などの分野で新薬候補が複雑化していることです。これらの複雑な治療薬には、高度に専門化された薬物動態サービスが必要であり、CROはそれを提供できる立場にあります。特に個別化医療の台頭は、薬物の代謝、分布、排泄における個人差に焦点を当てた薬物動態試験の需要を促進し、アウトソーシング市場の成長をさらに後押ししています。

薬物動態サービス市場の成長促進要因は？

薬物動態サービス市場の開拓は、技術革新、医薬品開発の複雑化、アウトソーシングの増加傾向など、いくつかの要因によって推進されています。主な要因の一つは、個別化医療に対する需要の高まりであり、薬物動態学研究は、個人の遺伝的差異が薬物代謝にどのように影響するかを理解するために不可欠です。この動向は薬物動態サービス市場を拡大しており、製薬会社は個別化治療レジメンをサポートするため、より正確で個別化されたデータを必要としています。さらに、医薬品パイプラインにおける生物製剤やバイオシミラーの普及が進んでいることも、高度な薬物動態サービスの需要を押し上げています。これらの複雑な分子はユニークな薬物動態プロファイルを持ち、従来の低分子医薬品を超える専門的な分析を必要とします。より多くの生物学的製剤が臨床開発を開始するにつれて、特にがん、自己免疫疾患、希少遺伝性疾患をターゲットとする治療薬では、テーラーメイドの薬物動態試験のニーズが高まり続けるでしょう。国際共同治験の拡大も薬物動態サービス市場の成長に寄与しています。製薬会社は複数の地域で医薬品を上市しようとするため、多様な規制要件に準拠する必要があり、地域固有の薬物動態データが必要となります。このため、複数の地域で試験を実施し、さまざまな患者集団にまたがる包括的な薬物動態データを提供できるCROへの需要が高まっています。最後に、規制状況は進化し続けており、FDAやEMAなどの機関は医薬品承認プロセスにおいて薬物動態データをより重視しています。このため、製薬会社は薬物動態試験により多額の投資を行い、規制への準拠を確保し、後期臨床段階での失敗のリスクを最小限に抑えようとしています。特に新規治療に対する規制要件の複雑化により、高品質の薬物動態サービスに対する需要がさらに高まると予想されます。

調査対象企業の例（全34件）

  • Biologics Consulting Group, Inc.
  • Certara L.P.
  • Charles River Laboratories International, Inc.
  • Creative Bioarray
  • Eurofins Scientific, Inc.
  • Evotec AG
  • Frontage Labs
  • GVK Biosciences Private Limited
  • LGC Limited
  • Pacific BioLabs
  • Parexel International Corporation
  • Pharmaceutical Product Development, LLC
  • Product Development, LLC（Jaguar Holding Company I, LLC）
  • SGS SA
  • Shanghai Medicilon Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP22510

Global Pharmacokinetics Services Market to Reach US$1.6 Billion by 2030

The global market for Pharmacokinetics Services estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030. Small Molecules, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Large Molecules segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$271.9 Million While China is Forecast to Grow at 6.1% CAGR

The Pharmacokinetics Services market in the U.S. is estimated at US$271.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$249.2 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Pharmacokinetics Services Market – Key Trends & Drivers Summarized

Why Are Pharmacokinetics Services Crucial in Drug Development?

Pharmacokinetics services are a fundamental component of the drug development process, playing a critical role in understanding how a drug moves through the body—its absorption, distribution, metabolism, and excretion (ADME). These services provide insights into the drug’s behavior, helping researchers determine the optimal dosage, frequency, and delivery method for therapeutic efficacy. The data generated from pharmacokinetics studies are crucial for ensuring the safety and effectiveness of new drugs before they reach clinical trials and, eventually, the market. Through detailed analysis, pharmacokinetics services assess how long a drug remains active in the system, how it is broken down in the liver, and how efficiently it is eliminated, all of which are vital for minimizing side effects and maximizing patient outcomes.

In the highly competitive pharmaceutical industry, pharmacokinetics services help reduce the risk of late-stage drug failures by identifying potential issues early in the development cycle. These services are particularly critical for drugs with narrow therapeutic windows, where precise dosing is essential to avoid toxicity or ineffective treatment. By providing a detailed map of the drug’s journey through the body, pharmacokinetics services allow for more informed decision-making in the design of clinical trials, ultimately improving the likelihood of successful regulatory approval.

How Are Technological Advancements Shaping the Pharmacokinetics Services Market?

The integration of cutting-edge technologies has transformed pharmacokinetics services, enhancing their precision, speed, and scalability. One of the most significant advancements is the use of high-throughput screening (HTS) technologies, which allow for the rapid assessment of multiple drug candidates simultaneously. HTS, combined with advanced computational models, enables more efficient prediction of a drug’s pharmacokinetics profile at earlier stages of development, reducing the need for extensive in-vivo studies and accelerating the timeline for candidate selection. Moreover, the application of artificial intelligence (AI) and machine learning (ML) has revolutionized data analysis in pharmacokinetics. AI algorithms can analyze vast datasets from pharmacokinetics studies to predict a drug’s behavior in various patient populations, offering insights that go beyond traditional statistical methods. These technologies also aid in identifying patterns that may indicate potential drug-drug interactions or adverse effects. AI-driven pharmacokinetics modeling has the potential to significantly reduce costs and time associated with drug development, allowing for more precise dosing regimens and personalized medicine approaches. Furthermore, advancements in bioanalytical techniques, such as mass spectrometry and liquid chromatography, have improved the sensitivity and accuracy of pharmacokinetics studies. These technologies allow researchers to detect and quantify drug concentrations in biological samples with greater precision, providing a more detailed understanding of how a drug is metabolized and excreted. The growing use of these technologies in pharmacokinetics services is driving the industry toward more robust and reliable data collection, which is essential for regulatory submissions and clinical trial design.

How Is Outsourcing of Pharmacokinetics Services Influencing the Market?

The outsourcing of pharmacokinetics services to specialized contract research organizations (CROs) has become a prevalent trend, as pharmaceutical and biotechnology companies look to streamline their drug development pipelines. Outsourcing allows companies to access the latest technologies, expertise, and infrastructure without the need for significant internal investments. This trend is particularly strong among small to mid-sized pharmaceutical companies, which may lack the resources to conduct in-house pharmacokinetics studies.

By partnering with CROs, these companies can take advantage of specialized pharmacokinetics services that are equipped with state-of-the-art bioanalytical tools and staffed by experts in drug metabolism and pharmacokinetics (DMPK). Outsourcing also offers the flexibility to scale services up or down based on the needs of individual drug development programs, making it a cost-effective solution for both early-stage and late-stage drug candidates. Additionally, the global reach of many CROs allows pharmaceutical companies to conduct pharmacokinetics studies across multiple geographic regions, which is crucial for addressing regulatory requirements in different markets.

Another key driver of outsourcing is the increasing complexity of new drug candidates, particularly in areas such as biologics, gene therapies, and personalized medicines. These complex therapeutics require highly specialized pharmacokinetics services, which CROs are well-positioned to provide. The rise of personalized medicine, in particular, is driving demand for pharmacokinetics studies that focus on individual variability in drug metabolism, distribution, and excretion, further fueling the growth of the outsourcing market.

What Are the Key Drivers of Growth in the Pharmacokinetics Services Market?

Growth in the pharmacokinetics services market is driven by several factors, including technological innovations, increasing complexity in drug development, and the rising trend of outsourcing. One of the primary drivers is the growing demand for personalized medicine, where pharmacokinetics studies are essential for understanding how individual genetic differences affect drug metabolism. This trend has expanded the market for pharmacokinetics services, as pharmaceutical companies require more precise and individualized data to support personalized treatment regimens. Additionally, the increasing prevalence of biologics and biosimilars in the pharmaceutical pipeline has driven demand for advanced pharmacokinetics services. These complex molecules have unique pharmacokinetics profiles, requiring specialized analysis that goes beyond traditional small-molecule drugs. As more biologics enter clinical development, the need for tailored pharmacokinetics studies will continue to grow, particularly for therapies targeting oncology, autoimmune diseases, and rare genetic disorders. The expansion of global clinical trials has also contributed to the growth of the pharmacokinetics services market. As pharmaceutical companies seek to bring drugs to market in multiple regions, they must comply with diverse regulatory requirements, necessitating region-specific pharmacokinetics data. This has led to increased demand for CROs that can conduct multi-regional studies and provide comprehensive pharmacokinetics data across various patient populations. Lastly, the regulatory landscape continues to evolve, with agencies such as the FDA and EMA placing greater emphasis on pharmacokinetics data in drug approval processes. This has driven pharmaceutical companies to invest more heavily in pharmacokinetics studies to ensure regulatory compliance and minimize the risk of late-stage clinical failures. The growing complexity of regulatory requirements, particularly for novel therapies, is expected to further propel the demand for high-quality pharmacokinetics services.

Select Competitors (Total 34 Featured) -

  • Biologics Consulting Group, Inc.
  • Certara L.P.
  • Charles River Laboratories International, Inc.
  • Creative Bioarray
  • Eurofins Scientific, Inc.
  • Evotec AG
  • Frontage Labs
  • GVK Biosciences Private Limited
  • LGC Limited
  • Pacific BioLabs
  • Parexel International Corporation
  • Pharmaceutical Product Development, LLC
  • Product Development, LLC (Jaguar Holding Company I, LLC)
  • SGS SA
  • Shanghai Medicilon Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Pharmacokinetics Services - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Pharmacokinetics Services in Drug Discovery and Development Drives Growth in Outsourced Research Support
    • Increasing Focus on Personalized Medicine and Tailored Therapies Propels Growth in Pharmacokinetics Studies for Customized Treatment Plans
    • Expansion of Biologics, Biosimilars, and Advanced Therapeutics Strengthens Demand for Pharmacokinetics Services in Preclinical and Clinical Trials
    • Technological Advancements in Pharmacokinetic Modeling and Simulation Tools Enhance Drug Development Efficiency and Predictive Accuracy
    • Growing Adoption of In Silico and In Vitro Pharmacokinetics Methods Expands Market for Non-Animal Testing Alternatives
    • Rising Stringency of Regulatory Requirements for Drug Absorption, Distribution, Metabolism, and Excretion (ADME) Testing Drives Growth in Pharmacokinetics Services
    • Increased Focus on Safety and Efficacy Testing for New Drug Applications Fuels Demand for Comprehensive Pharmacokinetics Studies
    • Growing Use of Pharmacokinetics in Determining Drug Dosing, Bioavailability, and Toxicity Profiles in Early-Stage Development
    • Emerging Use of Population Pharmacokinetics to Support Clinical Decision-Making and Dose Optimization in Specific Patient Populations
    • Rising Need for Pharmacokinetics Services in the Development of Orphan Drugs and Rare Disease Therapies
    • Technological Innovations in LC-MS/MS and Other Bioanalytical Techniques Enhance Data Accuracy in Pharmacokinetics Studies
    • Increased Outsourcing of Pharmacokinetics Studies to Contract Research Organizations (CROs) for Cost Efficiency and Expertise
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Pharmacokinetics Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Pharmacokinetics Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Pharmacokinetics Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Pharmacokinetics Services Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • JAPAN
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • CHINA
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • EUROPE
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Pharmacokinetics Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Pharmacokinetics Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Pharmacokinetics Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • FRANCE
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • GERMANY
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Rest of Europe Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Rest of Europe 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Asia-Pacific 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of World Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of World 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030

IV. COMPETITION